{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T08:09:09Z","timestamp":1779350949986,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 82273347"],"award-info":[{"award-number":["No. 82273347"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Clinical Research Foundation of Central High-level Hospital","award":["No. 2023HQ6"],"award-info":[{"award-number":["No. 2023HQ6"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-43393-z","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T15:16:21Z","timestamp":1775142981000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of RC48 alone or combined with PD-1 inhibitors in high-risk non-muscle invasive bladder cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Xuanjun","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuoyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yechi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuke","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yicong","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaiwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhisong","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqing","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuijian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"issue":"3","key":"43393_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2022","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74 (3), 229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834 (2022).","journal-title":"CA Cancer J. Clin."},{"key":"43393_CR2","doi-asserted-by":"publisher","unstructured":"LenisAT, LecPM, Chamie, K. & MshsMD Bladder Cancer: A Review. Jama 324 (19), 1980\u20131991. https:\/\/doi.org\/10.1001\/jama.2020.17598 (2020).","DOI":"10.1001\/jama.2020.17598"},{"key":"43393_CR3","doi-asserted-by":"crossref","unstructured":"Tan, X. et al. Prognostic Significance of HER2 Expression in Patients with Bacillus Calmette-Gu\u00e9rin-exposed Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. ;7(4):760\u2009\u2013\u20099.10.1016\/j.euo.2023.10.003 (2024).","DOI":"10.1016\/j.euo.2023.10.003"},{"key":"43393_CR4","doi-asserted-by":"crossref","unstructured":"Balar, A. V. et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. ;22(7):919\u2009\u2013\u200930.10.1016\/s1470-2045(21)00147-9 (2021).","DOI":"10.1016\/S1470-2045(21)00147-9"},{"key":"43393_CR5","doi-asserted-by":"crossref","unstructured":"Black, P. C. et al. Phase 2 Trial of Atezolizumab in Bacillus Calmette-Gu\u00e9rin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605. Eur Urol. ;84(6):536\u2009\u2013\u200944.10.1016\/j.eururo.2023.08.004 (2023).","DOI":"10.1016\/j.eururo.2023.08.004"},{"key":"43393_CR6","doi-asserted-by":"crossref","unstructured":"Hahn, N. M. et al. A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study. European Urology. ;83(6):486\u2009\u2013\u200994.10.1016\/j.eururo.2023.01.017 (2023).","DOI":"10.1016\/j.eururo.2023.01.017"},{"key":"43393_CR7","doi-asserted-by":"publisher","unstructured":"Wei, Y. et al. Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center\u2019s real-world study. Front. Pharmacol. 14 https:\/\/doi.org\/10.3389\/fphar.2023.1230395 (2023).","DOI":"10.3389\/fphar.2023.1230395"},{"key":"43393_CR8","doi-asserted-by":"crossref","unstructured":"Sheng, X. et al. Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials. J Clin Oncol. ;42(12):1391\u2009\u2013\u2009402.10.1200\/jco.22.02912 (2024).","DOI":"10.1200\/JCO.22.02912"},{"key":"43393_CR9","doi-asserted-by":"crossref","unstructured":"Zhou, L. et al. Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib\/II dose-escalation and dose-expansion study. Ann Oncol. ;36(3):331\u2009\u2013\u20099.10.1016\/j.annonc.2024.12.002 (2025).","DOI":"10.1016\/j.annonc.2024.12.002"},{"key":"43393_CR10","doi-asserted-by":"crossref","unstructured":"Chen, J. et al. Adjuvant or rescue disitamab vedotin (RC48-ADC) for high-risk non-muscle invasive bladder cancer with HER2 overexpression: A phase II multi-center study. Journal of Clinical Oncology. ;42.10.1200\/jco.2024.42.16_suppl.tps4625 (2024).","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4625"},{"issue":"6","key":"43393_CR11","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","volume":"86","author":"P Gontero","year":"2024","unstructured":"Gontero, P. et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-A Summary of the 2024 Guidelines Update. Eur. Urol. 86 (6), 531\u2013549. https:\/\/doi.org\/10.1016\/j.eururo.2024.07.027 (2024).","journal-title":"Eur. Urol."},{"issue":"6","key":"43393_CR12","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","volume":"86","author":"P Gontero","year":"2024","unstructured":"Gontero, P. et al. European Association of Urology Guidelines on Non\u2013muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)\u2014A Summary of the 2024 Guidelines Update. Eur. Urol. 86 (6), 531\u2013549. https:\/\/doi.org\/10.1016\/j.eururo.2024.07.027 (2024).","journal-title":"Eur. Urol."},{"key":"43393_CR13","doi-asserted-by":"crossref","unstructured":"Li, R. et al. Bladder-sparing Therapy for Bacillus Calmette-Gu\u00e9rin-unresponsive Non-muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection. Eur Urol. ;86(6):516\u2009\u2013\u200927.10.1016\/j.eururo.2024.08.001 (2024).","DOI":"10.1016\/j.eururo.2024.08.001"},{"key":"43393_CR14","unstructured":"U.S. Food and Drug Administration. Bacillus Calmette-Gu\u00e9rin-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biological Products for Treatment. (2018)."},{"key":"43393_CR15","doi-asserted-by":"crossref","unstructured":"Lamm, D. et al. Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition. J Urol. ;191(1):20\u2009\u2013\u20097.10.1016\/j.juro.2013.07.102 (2014).","DOI":"10.1016\/j.juro.2013.07.102"},{"key":"43393_CR16","doi-asserted-by":"crossref","unstructured":"Hong, X. et al. A HER2-targeted Antibody\u2010Drug Conjugate, RC48\u2010ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer. Advanced Science. ;10(32).10.1002\/advs.202302377 (2023).","DOI":"10.1002\/advs.202302377"},{"key":"43393_CR17","doi-asserted-by":"publisher","unstructured":"Chen, X. et al. Intravesical Disitamab Vedotin (RC48) for HER2-Expressing High\u2010Risk Non\u2010Muscle\u2010Invasive Bladder Cancer: A Single\u2010Arm, Dose\u2013Escalation Phase I Trial Study. MedComm 6 (7). https:\/\/doi.org\/10.1002\/mco2.70288 (2025).","DOI":"10.1002\/mco2.70288"},{"key":"43393_CR18","doi-asserted-by":"crossref","unstructured":"Giannarini, G. et al. Urologists, You\u2019ll Never Walk Alone! How Novel Immunotherapy and Modern Imaging May Change the Management of Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. ;5(3):268\u2009\u2013\u200972.10.1016\/j.euo.2021.05.008 (2022).","DOI":"10.1016\/j.euo.2021.05.008"},{"issue":"3","key":"43393_CR19","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.eururo.2020.02.012","volume":"78","author":"R Li","year":"2020","unstructured":"Li, R. et al. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Gu\u00e9rin. Eur. Urol. 78 (3), 387\u2013399. https:\/\/doi.org\/10.1016\/j.eururo.2020.02.012 (2020).","journal-title":"Eur. Urol."},{"key":"43393_CR20","doi-asserted-by":"crossref","unstructured":"Kamat, A. M. et al. Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis. Eur Urol Oncol. ;3(3):318\u2009\u2013\u200940.10.1016\/j.euo.2020.02.006 (2020).","DOI":"10.1016\/j.euo.2020.02.006"},{"issue":"8","key":"43393_CR21","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/s41419-023-06073-8","volume":"14","author":"X Wu","year":"2023","unstructured":"Wu, X. et al. A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway. Cell. Death Dis. 14 (8), 550. https:\/\/doi.org\/10.1038\/s41419-023-06073-8 (2023).","journal-title":"Cell. Death Dis."},{"issue":"2","key":"43393_CR22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","volume":"17","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi, L., Buqu\u00e9, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 17 (2), 97\u2013111. https:\/\/doi.org\/10.1038\/nri.2016.107 (2017).","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"43393_CR23","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1158\/1078-0432.CCR-23-1725","volume":"30","author":"Q Wei","year":"2024","unstructured":"Wei, Q. et al. Spatiotemporal Quantification of HER2-targeting Antibody-Drug Conjugate Bystander Activity and Enhancement of Solid Tumor Penetration. Clin. Cancer Res. 30 (5), 984\u2013 (2024). \u2013\u200997.10.1158\/1078\u2009\u2013\u20090432.Ccr-23-1725.","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"43393_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13058-020-1252-7","volume":"22","author":"A Oca\u00f1a","year":"2020","unstructured":"Oca\u00f1a, A., Amir, E. & Pandiella, A. HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates. Breast Cancer Res. 22 (1), 15\u2013101186s13058 (2020).","journal-title":"Breast Cancer Res."},{"key":"43393_CR25","doi-asserted-by":"crossref","unstructured":"Lei, H. et al. Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer. J Natl Cancer Cent. ;3(2):121\u2009\u2013\u20098.10.1016\/j.jncc.2023.02.003 (2023).","DOI":"10.1016\/j.jncc.2023.02.003"},{"key":"43393_CR26","doi-asserted-by":"crossref","unstructured":"Ge, H. et al. The effectiveness and safety of RC48 alone or in combination with PD-1 inhibitors for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study. J Transl Med. ;23(1):243.10.1186\/s12967-025-06237-4 (2025).","DOI":"10.1186\/s12967-025-06237-4"},{"key":"43393_CR27","doi-asserted-by":"crossref","unstructured":"Khongorzul, P., Ling, C. J., Khan, F. U., Ihsan, A. U. & Zhang, J. Antibody\u2013Drug Conjugates: A Comprehensive Review. Molecular Cancer Research. ;18(1):3-19.10.1158\/1541\u20137786.MCR-19-0582 (2020).","DOI":"10.1158\/1541-7786.MCR-19-0582"},{"issue":"2","key":"43393_CR28","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow, P. MA, Sidlow, R. & HellmannMD Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl. J. Med. 378 (2), 158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481 (2018).","journal-title":"N Engl. J. Med."},{"key":"43393_CR29","doi-asserted-by":"publisher","first-page":"103960","DOI":"10.1016\/j.critrevonc.2023.103960","volume":"184","author":"Z Zhu","year":"2023","unstructured":"Zhu, Z. et al. Incidence of antibody-drug conjugates-related pneumonitis in patients with solid tumors: A systematic review and meta-analysis. Crit. Rev. Oncol. Hematol. 184, 103960. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.103960 (2023).","journal-title":"Crit. Rev. Oncol. Hematol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43393-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43393-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43393-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T07:35:00Z","timestamp":1779348900000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-43393-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["43393"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-43393-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocol was approved by the Ethics Committee of Peking University First Hospital (Approval No.: 2025R0556). The requirement for informed consent was waived by the ethics committee given the participants could not be contacted due to the retrospective nature of the research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"15796"}}